1 Intracellular microelectrode recording techniques were performed on mouse spinal cord and cerebral hemisphere neurones grown in primary dissociated cell culture. The effects of several anxiolytics applied by local pressure ejection on responses to y-aminobutyric acid (GABA) evoked by iontophoresis were investigated. Responses to GABA were depolarizing since intracellular chloride ion concentration was increased by injection from potassium chloride (3M)-filled recording micropipettes and neurones were held at large negative membrane potentials (-70 to -90mV). The agents studied were six 'non-sedative anxiolytics ', CL 218, 1,2,4-triazolo(4,3-b) pyridazine), PK 8165 (2-phenyl-442-(4-piperidinyl)
Introduction
The benzodiazepines, in addition to their anxiolytic and anticonvulsant properties, have sedative effects (Fink & Swinyard, 1962; Haefely et al., 1981) , and the use of these drugs is associated with the development of tolerance and dependence (Allgulander, 1978) . As a result there has been a continuing effort to develop selective, non-sedative anxiolytic drugs. Several benzodiazepine receptor ligands and nonbenzodiazepine receptor ligands have been proposed in this respect. Some of these compounds have been suggested to be devoid of induction of tolerance and/or dependence (Lamb & Griffiths, 1984; Gerhardt et al., 1985) .
Six novel compounds, suggested to be anxiolytic drugs, are considered in this study : CL 218, methyl-6-(3-trifluoromethylphenyl)1,2,4-triazolo(4,-3-b) pyridazine), PK 8165 (2-phenyl4-(2(4-piperidinyl) ethyl)-quinoline), PK 9084 (2-phenyl-4-(243-piperidinyl)ethyl)-quinoline), CGS 9896 (2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one), ZK 91296 (ethyl 5-benzyloxy-4-methoxymethyl-pcarboline-3-f-carboxylate) and buspirone (8-4-[4-(2- pyrimidinyl ) -1 -piperazinyl ] butyl -8 -azaspiro [4.5] decane-7,9-dione). All of these compounds have been demonstrated to display a non-sedative anxiolytic behavioural profile. CL 218,872 was shown to be a central benzodiazepine receptor ligand (Squires et al., 1979; Lippa et al., 1979ab) . This triazolopyridazine was found to be relatively free of ataxic and depressant side-effects, to increase punished responding in a conflict procedure and to protect against pentylenetetrazol-induced seizures (Squires et al., 1979; Lippa et al., 1979b) . However, the initial results indicating that CL 218,872 is nonsedative have not been confirmed File et al., 1985; McElroy et al., 1985) . PK 8165 and PK 9084 are both phenylquinolines and were found to have a non-sedative anxiolytic profile (Le Fur et al., 1981) . However, subsequent investigators have failed to substantiate that the phenylquinolines are non-sedative (File & Lister, 1983;  File, 1983 ; Keane et al., 1984) . Both phenylquinolines have been suggested to be partial agonists at the benzodiazepine receptor Gee et al., 1983; Benavides et al., 1984) . CGS 9896, a pyrazoloquinoline, (Yokoyama et al., 1982) and ZK 91296, a fl-carboline, (Petersen et al., 1984; Pellow & File, 1986) were shown to be non-sedative anxiolytics and to protect against pentylenetetrazolinduced seizures. Both CGS 9896 (Yokoyama et al., 1982; and ZK 91296 (Petersen et al., 1984) are known to be benzodiazepine receptor ligands. Buspirone, a piperazinyl pyrimidine, is a non-benzodiazepine receptor ligand with anticonflict activity (Riblet et al., 1982; Geller & Hartmann, 1982) . Several clinical trials have confirmed the non-sedative anxiolytic profile of this compound (Goldberg & Finnerty, 1979; Rickels et al., 1982; Newton et al., 1982) .
Diazepam and zopiclone ([6-(5-chloro-2-pyridyl-6,7-dihydro-7-oxo-5 H-pyrrolo [3,4-b] pyrazine-5-yl] 4-methyl-1-piperazinecarboxylate) were included as sedative anxiolytic drugs. Diazepam is a benzodiazepine receptor agonist , displaying all benzodiazepine-like activities, i.e., anxiolytic, anticonvulsant, sedative and muscle relaxant effects. The pyrrolopyrazine zopiclone, believed to be a benzodiazepine receptor ligand (Blanchard et al., 1979; 1983) , has a similar benzodiazepine-like pharmacological profile in animal models and in clinical trials ((Duriez et al., 1979; Julou et al., 1983) . It has been suggested that Zopiclone interacts allosterically with the benzodiazepine receptor complex (Trifiletti & Snyder, 1984) .
Various lines of evidence support the hypothesis that facilitation of the postsynaptic responses to yaminobutyric acid (GABA) is involved in many of the actions of the benzodiazepines (Choi et al., 1977; Macdonald & Barker, 1978; Haefely et al., 1979; Costa & Guidotti, 1979) , the barbiturates (Nicoll et al., 1975; Macdonald & Barker, 1979; Haefely et al., 1979) and related central nervous system depressants. In this study we evaluated the effects of six 'non-sedative' and two 'sedative' anxiolytic agents on responses to GABA (Macdonald & Barker, 1979; Nowak et al., 1982) , and on diazepam-induced enhancement of responses to GABA, on mouse spinal cord and cerebral hemisphere neurones grown in primary dissociated cell culture. In addition, the effects of the benzodiazepine receptor antagonists Ro 15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo (1,5a)1,4)-benzodiazepine-3-carboxylate) and CGS 8216 (2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one) on the drug-induced alteration of responses to GABA were studied in mouse spinal cord neurones.
Methods
Primary dissociated cell culture Cultures of spinal cord neurones were prepared from dissected spinal cords and attached dorsal root ganglia from 12-14 day old foetal mice as described previously (Ransom et al., 1977) . The tissue was minced and then mechanically dissociated by trituration in Ca2+-, and Mg2+-free balanced salt solution to a suspension of single cells and small clumps. The dissociated cells were suspended in culture medium (90% Eagle's minimal essential medium supplemented with 5.5 g l-1 of glucose and 1.5 g I1-of NaHCO3, 5% heat-inactivated horse serum and 5% Nu-Serum II (Collaborative Research Inc., Lexington, MA, U.S.A.), 325 mOsmol) and then plated on sterile collagen-coated 35mm dishes. Each cord produced 6 to 8 cultures. The cultures were maintained in an incubator with an atmosphere of 93% room air and 7% CO2 at 350C. The bicarbonate/CO2 buffer maintained pH at 7.4. 5-Fluoro-2'-deoxyuridine was added to the cultures on days 6 to 8 in order to suppress the growth of rapidly dividing non-neuronal cells. Medium was changed twice weekly. Cultures were maintained for 4 to 9 weeks before electrophysiological experiments.
Cerebral hemisphere cultures were prepared from 14-to 18-day gestational mice after transection of the cervical cord. The cerebral hemispheres were dissected away from the brainstem. The pieces of lateral cortical mantle were pooled separately in Ca2 +-, Mg2+-free balanced salt solution. After replacement of the balanced salt solution with culture medium, the pieces were dissociated mechanically, plated on collagen-coated dishes (12 to 14 cultures perhemisphere) and maintained as described above.
Experimental procedures
Solutions All recordings were made in a Dulbecco's phosphate buffered saline after removal of growth medium. The recording solution, with elevated magnesium ion concentration in order to suppress spontaneous activity, contained in mM: NaCl 137, Na2HPO4 8.06, KCI 2.68, KH2PO4 1.47, CaCl2 1.0, MgCl2 10 and glucose 5.6 (pH 7.3-7.4). Heavy paraffin oil was applied to the surface of the bathing solution to retard evaporation.
Solutions of the tested drugs were always prepared on the day of the experiment in the following manner. The dry drugs were dissolved in dimethylsulphoxide to form a 1 or 10mM stock solution. Aliquots were removed and diluted in bathing medium to give concentrations between 1 nm and 100pM. These final solutions contained 0.1% or less dimethylsulphoxide. Responses to GABA GABA (0.5 M, pH 3.4) was applied iontophoretically using 5OOms duration rectangular positive current pulses at 5s intervals. Iontophoretic pipettes were positioned to within 2ym of neuronal somata. The use of 3 M KCl-filled micropipettes shifted the chloride equilibrium potential from about -65 mV to about -20 mV. Under these conditions, an increase of chloride conductance resulted in an outward chloride current (Nishi et al., 1974) , giving depolarizing responses to GABA . Responses to GABA of about 10 to 15 mV in amplitude were evoked following membrane hyperpolarization (to -70 to -90 mV) to avoid saturation at or near the chloride equilibrium potential. In studies of drug effects on responses to GABA, data were accepted only if responses to GABA returned to control amplitude within 5 min of removal of the drug-containing micropipette. In studies of antagonists, data were accepted only if the original direct effect of the agonist returned after removal of the tested putative antagonist. Drug application For evaluation of drug effects on responses to GABA, all drugs were applied by pressure ejection. A blunt tipped (5-10pm) micropipette, filled with the test solution, was positioned 15-30.pm from the soma of the cell under study. The open end of each pressure ejection micropipette was connected by tight fitting polyethylene tubing to a pressure regulator, set between 0.4 and 0.8 pounds per square inch (psi). Pressure pulse duration, regulated by a voltage-activated 3-way valve, was 10s. Under these conditions, application of control solutions was virtually free of effects. Pressure and position of the pressure ejection micropipettes were adjusted to attain a maximal drug response. We have demonstrated previously that the concentrationdependency of drug action determined using pressure ejection or by superfusion are equivalent if this experimental procedure is used (Heyer et al., 1982) . For assessment of possible antagonistic effects at the benzodiazepine receptor, the putative antagonist was applied by diffusion from a large tipped (10- 20.pm) micropipette, before application by pressure ejection of the anxiolytic drug. As a control, record-ing solution alone or with vehicle was applied by diffusion and was without effect. To decrease leakage of drugs into the bathing medium, the tips of the pressure ejection micropipettes were kept in the oil phase between drug application trials. They were lowered into the aqueous phase only when drug application was desired. Effects of diazepam, zopiclone, PK 8165 and CL 218,872 on responses to GABA recorded from spinal cord neurones were concentration-dependent ( Figure  2 ). For diazepam, enhancement of responses to GABA was produced at lOnm and peak enhancement occurred at 500nm. A lesser enhancement was observed at higher concentrations. For zopiclone, enhancement was observed at 50 nm, and the enhancement was concentration-dependent up to 1OyM. PK 8165 enhanced responses to GABA at 10, 100 and 500 nm. However, at a concentration of 1 gm, PK 8165 was without effect. In contrast, at concentrations higher than 1 pM, PK 8165 reversibly reduced responses to GABA. For CL 218,872, enhancement was observed at 100 nm, and the enhancement was concentration-dependent up to 1OpM.
Drugs
CGS 9896, ZK 91296, PK 9084 and buspirone, however, had no significant direct effect on responses to GABA at concentrations ranging from 1 nm to 1O JM (Table 1) .
Antagonism ofdiazepam-induced enhancement of responses to GABA Attempts were made to antagonize the diazepam (100 nM)induced enhancement of the response to GABA by the compounds that did not display a significant direct effect on the response to GABA. These drugs were: CGS 9896, ZK 91296, PK 9084 and buspirone. The % increases of responses to GABA by diazepam with and without co-application of control or drug-containing solution were compared. Diazepam-induced enhancement of responses to GABA was unaffected by co-application of recording solution alone or with vehicle (96 + 7.1% (n = 8)).
CGS 9896 (1 pM, n = 5) ( Figure 3a ) and ZK 91296 (1 pM, n = 5) (Figure 3b ) almost completely antagonized diazepam-induced enhancement of responses to GABA. However, PK 9084 (1OpM, n = 6) ( Figure   3c ) and buspirone (1OpM, n = 5) (Figure 3d) (Figure 5a , Table 2 ). Ro 15-1788 enhanced responses to GABA by 7.5% at lOOnM and by 15.1% at 500 nm ( Figure 5 , Table  2 ). In the presence of Ro 15-1788 (500nM), diazepam (100 nM)-induced enhancement of responses to GABA was significantly reduced to 9.4% (Table 2) . Zopiclone (500nM) enhanced responses to GABA by 43.8% ( Figure Sb, Table 2 ). In the presence of Ro 15-1788 (100nM), the zopiclone (500nM)induced increase of the response to GABA was significantly reduced to 19.3% ( Figure 5b , Table 2 ). Table 2 ). However, CL 218,872 was without significant effect on the response to GABA after diffusion of Ro 15-1788 (500 nM) ( Figure  5c , Table 2 ). At a low concentration (10 nM) PK 8165 enhanced responses to GABA by 25.6% but had no significant effect on responses to GABA when applied after diffusion of Ro 15-1788 (500 nM) ( Figure  5d , Table 2 ). At a high concentration (1OpM), PK 8165 reduced responses to GABA by 38.8% (Table   Table 2 antagonist or weak partial agonist at the benzodiazepine receptor (Hunckeler et al., 1981; Skerritt & Macdonald, 1983) , antagonized these effects, suggesting that the benzodiazepine receptor may be the site of action for these anxiolytics. These findings are consistent with previous results for diazepam (Squires & Braestrup, 1977; Mohler & Okada, 1977) , zopiclone (Blanchard et al., 1979; 1983; Trifiletti & Snyder, 1984) (Skerritt & Macdonald, 1984 (Riblet et al., 1982) . However, for the phenylquinolines PK 9084 and PK 8165, the binding studies were less conclusive. While shown to be benzodiazepine receptor ligands in vitro (Gee et al., 1983; Benavides et al., 1984 ; Keane et al., 1984) , one in vivo study (Keane et al., 1984) failed to demonstrate an affinity for the benzodiazepine receptor. The data presented in this study are not entirely consistent with a unitary hypothesis that these drugs are anxiolytic and anticonvulsant by directly enhancing postsynaptic GABAergic inhibition. The classification of diazepam and zopiclone (Haefely et al., 1979; Duriez et al., 1979; Julou et al., 1983) as full agonists and CL 218,872 (Squires et al., 1979; Lippa et al., 1979b) and PK 8165 (Le Fur et al., 1981) as partial agonists at the benzodiazepine receptor is consistent with their anxiolytic action. Administered at relatively high doses, PK 8165 was proconvulsant (File & Simmonds, 1984) . This is consistent, as suggested by our findings, with an action of this compound mediated via a receptor independent of the benzodiazepine receptor. Several neurochemical parameters, such as GABA-ratio, photo shift, chloride shift and TBPS shift (Ehlert et al., 1982; Karobath et al., 1983; Wood et al., 1984) are consistent with our findings that diazepam, zopiclone, CL 218,872 and PK 8165 have agonist or partial agonist actions on benzodiazepine receptors. A discrepancy, however, was found between the lack of direct effects on responses to GABA on mouse spinal cord and hemisphere neurones for the benzodiazepine-receptor ligands CGS 9896 and ZK 91296 and their anxiolytic and anticonvulsant actions (Yokoyama et al., 1982; Petrack et al., 1983; Petersen et al., 1984) . Neurochemical studies predicted a partial agonistic profile for CGS 9896 and ZK 91296 Petersen et al., 1984) . However, the benzodiazepine receptor antagonist effects of CGS 9896 and ZK 91296 obtained in this study are consistent with the behavioural findings (Brown et al., 1984; Bernard et al., 1985; Klockgether et al., 1985) . The existence of an endogenous ligand for the benzodiazepine receptor could explain the lack of an intrinsic effect of CGS 9896 and ZK 91296 in our experimental system, as opposed to behavioural and neurochemical findings. The interaction of an endogenous ligand with anxiogenic and proconvulsant activity could explain the absence of intrinsic activity in vitro and the observed selective agonist activity in vivo for CGS 9896 and ZK 91296. The existence of an endogenous anxiogenic benzodiazepine receptor ligand has indeed been suggested (Guidotti et al., 1982; Costa & Guidotti, 1985) .
Another hypothesis for the non-sedative anxiolytic profile of benzodiazepine receptor ligands could be the mediation of their pharmacological effects via specific benzodiazepine receptor subtypes. Only for CL 218,872 Squires et al., 1979) and CGS 9896 have different affinities for benzodiazepine receptors in different brain regions been proposed. For CL 218,872, its specific interaction with a cerebellar subtype of benzodiazepine receptor (Type I) has been suggested as the basis for its selective anxiolytic effect . However, the pharmacological significance of this receptor subtype has been challenged because the discriminitive properties of CL 218,872 disappear at 370C . Moreover, this triazolopyridazine concentration-dependently enhanced responses to GABA on our non-cerebellar neurones. A recent study, using autoradiographic techniques, showed a significantly different affinity for CGS 9896, less than 2 times higher, for cerebellar cortex than for dentate gyrus . Practical implications of such a small difference in affinity seem unlikely, and moreover, the cerebellum is a brain region not believed to be related to anxiety but is rather involved in motor function.
Our findings failed to indicate any interaction of PK 9084 or buspirone with the benzodiazepine receptor complex. While PK 9084 is poorly established as an anxioselective agent, buspirone has been shown to be efficaceous in several clinical trials (Goldberg & Finnerty, 1979; Goldberg & Finnerty, 1982; Rickels et al., 1982) . These results are consistent with the conclusion that anxiety can be treated by modification of non-GABAergic neurotransmission, possibly including 5-hydroxytryptaminergic, noradrenergic and dopaminergic systems (for review, see: Hoehn-Saric, 1982; Braestrup, 1982) .
In conclusion, in a system testing postsynaptic responses to GABA, two clearly sedative anxiolytics, diazepam and zopiclone, were found to be full benzodiazepine receptor agonists. CL 218,872 and PK 8165, initially thought to be non-sedative anxiolytics but later shown to be sedative anxiolytics, were found to be partial benzodiazepine receptor agonists. These results are consistent with neurochemical and behavioural findings for these compounds and suggest that enhancement of GABAergic inhibition by benzodiazepine receptor agonists is anxiolytic and sedative. However, the non-sedative anxiolytics CGS 9896 and ZK 91296 were shown to be benzodiazepine receptor antagonists. PK 9084 and buspirone were found to be free of any interaction with the benzodiazepine receptor complex. Our electrophysiological findings together with other neurochemical and behavioural data suggest that facilitation of GABA-ergic neurotransmission may be sufficient, but not necessary for anxiolysis, that benzodiazepine receptor agonists produce sedative anxiolysis and that benzodiazepine receptor antagonists or weak partial agonists may produce non-sedative anxiolysis.
